Press Releases

Amprion brings intense focus to Alzheimer’s & Brain Health Awareness Month by expanding its quantitative study of the SYNTap Biomarker Test.

For the first time in history, Amprion’s breakthrough SYNTapÒ Biomarker Test can help doctors effectively distinguish Parkinson’s Disease (PD) from Parkinsonism early. This innovative test accurately detects the presence or absence of misfolded Synuclein, a crucial biomarker of these diseases, in spinal fluid.

We invite AAN Annual Meeting attendees to visit Amprion’s booth #1074 and meet our CEO/Co-Founder and clinical director.

A rapidly aging nation, the U.S. has 60 million people aged 65 and older. Of these, about 12 million people show early symptoms of Mild Cognitive Impairment. One in three of these people will progress to clinical Alzheimer’s disease (AD) within five years. New research studies reveal the complexity of AD, from classical Alzheimer’s to

Amprion Lab earns CAP accreditation. The SYNTap Test aids doctors in diagnosing LBD and PD. We’re racing to a cure through accurate biomarker testing.

Amprion announces SYNTap™ Biomarker Test for Alzheimer’s, Lewy Body Dementia & Parkinson’s.

FDA Grants Breakthrough Device Designation For Amprion’s PMCA Tests For Detection of Misfolded Alpha-Synuclein, Prion Known to Drive Parkinson’s